Enliven Therapeutics, Inc. (NASDAQ:ELVN) CFO Benjamin Hohl Sells 1,000 Shares of Stock

Enliven Therapeutics, Inc. (NASDAQ:ELVN) CFO Benjamin Hohl sold 1,000 shares of Enliven Therapeutics stock in a transaction that occurred on Monday, March 24th. The shares were sold at an average price of $22.50, for a total transaction of $22,500.00. Following the completion of the transaction, the chief financial officer now owns 23,000 shares of the company’s stock, valued at $517,500. This represents a 4.17 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink.

Benjamin Hohl also recently made the following trade(s):

• On Thursday, February 27th, Benjamin Hohl sold 3,250 shares of Enliven Therapeutics stock. The stock was sold at an average price of $20.41, for a total value of $66,332.50.
• On Wednesday, February 5th, Benjamin Hohl sold 1,000 shares of Enliven Therapeutics stock. The shares were sold at an average price of $22.52, for a total value of $22,520.00.
• On Monday, January 27th, Benjamin Hohl sold 3,250 shares of Enliven Therapeutics stock. The stock was sold at an average price of $21.59, for a total value of $70,167.50.
• On Friday, January 3rd, Benjamin Hohl sold 1,000 shares of Enliven Therapeutics stock. The shares were sold at an average price of $25.04, for a total value of $25,040.00.
• On Monday, December 30th, Benjamin Hohl sold 900 shares of Enliven Therapeutics stock. The shares were sold at an average price of $22.51, for a total transaction of $20,259.00.
• On Friday, December 27th, Benjamin Hohl sold 3,350 shares of Enliven Therapeutics stock. The shares were sold at an average price of $22.15, for a total transaction of $74,202.50.

Enliven Therapeutics Price Performance

Shares of ELVN opened at $20.58 on Thursday. Enliven Therapeutics, Inc. has a 1-year low of $15.96 and a 1-year high of $30.03. The company has a market capitalization of $1.01 billion, a P/E ratio of -10.83 and a beta of 1.04. The firm’s 50 day simple moving average is $21.29 and its 200 day simple moving average is $23.76.

Enliven Therapeutics (NASDAQ:ELVN) last announced its quarterly earnings data on Thursday, March 13th. The company reported ($0.46) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.53) by $0.07. The business had revenue of $0.03 million during the quarter. On average, equities analysts anticipate that Enliven Therapeutics, Inc. will post -1.95 earnings per share for the current year.

Analyst Upgrades and Downgrades

ELVN has been the subject of several analyst reports. BTIG Research started coverage on shares of Enliven Therapeutics in a report on Friday, December 13th. They issued a “buy” rating and a $42.00 price target for the company. HC Wainwright increased their price objective on Enliven Therapeutics from $37.00 to $39.00 and gave the stock a “buy” rating in a research report on Friday, March 21st. Four investment analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat.com, Enliven Therapeutics has a consensus rating of “Buy” and a consensus target price of $38.75.

Institutional Trading of Enliven Therapeutics

Several hedge funds have recently added to or reduced their stakes in the business. Wellington Management Group LLP increased its holdings in shares of Enliven Therapeutics by 15.3% in the fourth quarter. Wellington Management Group LLP now owns 80,916 shares of the company’s stock worth $1,821,000 after buying an additional 10,746 shares during the period. California State Teachers Retirement System grew its position in Enliven Therapeutics by 10.2% during the 4th quarter. California State Teachers Retirement System now owns 20,914 shares of the company’s stock worth $471,000 after acquiring an additional 1,940 shares during the last quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC grew its position in Enliven Therapeutics by 67.1% during the 4th quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 43,714 shares of the company’s stock worth $984,000 after acquiring an additional 17,546 shares during the last quarter. Stempoint Capital LP purchased a new position in Enliven Therapeutics in the 4th quarter worth approximately $2,176,000. Finally, Polar Capital Holdings Plc lifted its position in Enliven Therapeutics by 267.6% in the fourth quarter. Polar Capital Holdings Plc now owns 2,389,668 shares of the company’s stock valued at $53,768,000 after purchasing an additional 1,739,668 shares during the last quarter. 95.08% of the stock is owned by institutional investors.

About Enliven Therapeutics

Enliven Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. The company’s lead product candidates comprise ELVN-001, which is being evaluated in a Phase 1 clinical trial in adults with chronic myeloid leukemia; and ELVN-002, a Phase 1 clinical trial in adults with solid tumors with HER2 alterations.